enGene Holdings Inc. (NASDAQ:ENGN) Given Consensus Rating of “Hold” by Analysts

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average recommendation of “Hold” by the fourteen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $12.6818.

Several research analysts have recently weighed in on the stock. Citigroup downgraded shares of enGene from a “market outperform” rating to a “market perform” rating in a research report on Friday, May 8th. Oppenheimer downgraded shares of enGene from an “outperform” rating to a “market perform” rating in a research report on Friday, May 8th. WBB Securities assumed coverage on shares of enGene in a research report on Monday, April 13th. They issued a “buy” rating and a $21.50 target price on the stock. Morgan Stanley downgraded shares of enGene from an “overweight” rating to an “equal weight” rating in a research report on Friday, May 8th. Finally, Raymond James Financial downgraded shares of enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 target price on the stock. in a research report on Friday, May 8th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ENGN. Cresset Asset Management LLC purchased a new position in shares of enGene in the second quarter worth approximately $36,000. Paloma Partners Management Co purchased a new position in enGene during the second quarter valued at approximately $38,000. Raymond James Financial Inc. grew its position in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares in the last quarter. Braidwell LP purchased a new position in enGene during the third quarter valued at approximately $15,479,000. Finally, Citadel Advisors LLC grew its position in enGene by 153.3% during the third quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after purchasing an additional 35,327 shares in the last quarter. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Stock Performance

Shares of ENGN opened at $1.77 on Tuesday. The firm’s 50 day moving average is $4.31 and its 200-day moving average is $7.19. The stock has a market capitalization of $118.57 million, a P/E ratio of -0.79 and a beta of -0.29. The company has a debt-to-equity ratio of 0.09, a current ratio of 11.75 and a quick ratio of 11.75. enGene has a 12-month low of $1.40 and a 12-month high of $12.25.

enGene (NASDAQ:ENGN) last released its earnings results on Thursday, June 11th. The company reported $0.43 earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.91. During the same quarter in the previous year, the company earned $0.51 earnings per share. Equities research analysts anticipate that enGene will post -2.02 EPS for the current fiscal year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.